Runming Wang

Runming Wang

Auto-generated profile, based on publicly available information

Runming Wang

Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
RWRunming Wang
Runming Wang
TLTsz-Pui Lai
Tsz-Pui Lai
PGPeng GAO
Peng GAO
HZHongmin Zhang
Hongmin Zhang
PHPak-Leung HO
Pak-Leung HO
HSHongzhe Sun
Hongzhe Sun
Drug-resistant superbugs pose a huge threat to human health. Infections by Enterobacteriaceae producing metallo-β-lactamases (MBLs), e.g., New Delhi metallo-β-lactamase 1 (NDM-1) are very difficult to treat. Development of effective MBL inhibitors to revive the efficacy of existing antibiotics is highly desirable. However, such inhibitors are not clinically available till now. Here we show that an anti-Helicobacter pyloridrug, colloidal bismuth subcitrate (CBS), and related Bi(III) compounds irreversibly inhibit different types of MBLs via the mechanism, with one Bi(III) displacing two Zn(II) ions as revealed by X-ray crystallography, leading to the release of Zn(II) cofactors. CBS restores meropenem (MER) efficacy against MBL-positive bacteria in vitro, and in mice infection model, importantly, also slows down the development of higher-level resistance in NDM-1-positive bacteria. This study demonstrates a high potential of Bi(III) compounds as the first broad-spectrum B1 MBL inhibitors to treat MBL-positive bacterial infection in conjunction with existing carbapenems.

1 March 2013 in Chemical Engineering Journal
Verified
Journal Article
Closed access
JXJinyan Xiong
Jinyan Xiong
GCGang Cheng
Gang Cheng
FQFan Qin
Fan Qin
RWRunming Wang
Runming Wang
HSHongzhe Sun
Hongzhe Sun
RCRong Chen
Rong Chen

16 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SYShuofeng Yuan
Shuofeng Yuan
Xin YinXin Yin
Xin Yin
XMXiangzhi Meng
Xiangzhi Meng
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
ZYZi-Wei Ye
Zi-Wei Ye
KYKwok-Yung Yuen
Kwok-Yung Yuen

7 October 2020 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
SYShuofeng Yuan
Shuofeng Yuan
RWRunming Wang
Runming Wang
JCJasper Fuk-Woo Chan
Jasper Fuk-Woo Chan
AZAnna Jinxia Zhang
Anna Jinxia Zhang
TCTianfan Cheng
Tianfan Cheng
HSHongzhe Sun
Hongzhe Sun
SARS-CoV-2 is causing a pandemic of COVID-19, with high infectivity and significant mortality1. Currently, therapeutic options for COVID-19 are limited. Historically, metal compounds have found use as antimicrobial agents, but their antiviral activities have rarely been explored. Here, we test a set of metallodrugs and related compounds, and identify ranitidine bismuth citrate, a commonly used drug for the treatment of Helicobacter pylori infection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo. Ranitidine bismuth citrate exhibited low cytotoxicity and protected SARS-CoV-2-infected cells with a high selectivity index of 975. Importantly, ranitidine bismuth citrate suppressed SARS-CoV-2 replication, leading to decreased viral loads in both upper and lower respiratory tracts, and relieved virus-associated pneumonia in a golden Syrian hamster model. In vitro studies showed that ranitidine bismuth citrate and its related compounds exhibited inhibition towards both the ATPase (IC50 = 0.69 µM) and DNA-unwinding (IC50 = 0.70 µM) activities of the SARS-CoV-2 helicase via an irreversible displacement of zinc(ii) ions from the enzyme by bismuth(iii) ions. Our findings highlight viral helicase as a druggable target and the clinical potential of bismuth(iii) drugs or other metallodrugs for the treatment of SARS-CoV-2 infection.

16 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HSHongzhe Sun
Hongzhe Sun
QZQi Zhang
Qi Zhang
RWRunming Wang
Runming Wang
HWHaibo Wang
Haibo Wang
YWYuen-Ting Wong
Yuen-Ting Wong
HLHongyan Li
Hongyan Li
Global emergence of Gram-negative bacteria carrying the plasmid-borne resistance genes, blaMBL and mcr, raises a significant challenge to the treatment of life-threatening infections by the antibiotics, carbapenem and colistin (COL). Here, we identify an antirheumatic drug, auranofin (AUR) as a dual inhibitor of metallo-β-lactamases (MBLs) and mobilized colistin resistance (MCRs), two resistance enzymes that have distinct structures and substrates. We demonstrate that AUR irreversibly abrogates both enzyme activity via the displacement of Zn(II) cofactors from their active sites. We further show that AUR synergizes with antibiotics on killing a broad spectrum of carbapenem and/or COL resistant bacterial strains, and slows down the development of β-lactam and COL resistance. Combination of AUR and COL rescues all mice infected by Escherichia coli co-expressing MCR-1 and New Delhi metallo-β-lactamase 5 (NDM-5). Our findings provide potential therapeutic strategy to combine AUR with antibiotics for combating superbugs co-producing MBLs and MCRs.

22 October 2012 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FQFan Qin
Fan Qin
GLGuangfang Li
Guangfang Li
RWRunming Wang
Runming Wang
JWJiliang Wu
Jiliang Wu
HSHongzhe Sun
Hongzhe Sun
RCRong Chen
Rong Chen